Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Israeli, Jordanian researchers team on leishmaniasis treatment

The project brings together a consortium of parties from Israel, Jordan, and Switzerland for the treatment of the parasitic disease.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

Original Title: Sandfly_18-08.jpg
Researchers from Israel and Jordan are seeking a treatment for cutaneous leishmaniasis in a new project, initiated by Israeli research company Pharmaseed. The project brings together a consortium of parties from Israel, Jordan, and Switzerland for the treatment of cutaneous leishmaniasis, a variant of the parasitic disease leishmaniasis, also known as “Jericho buttons.” Leishmaniasis, which is transmitted by sandflies, is common in the Middle East. The mild manifestation of the condition causes sores that leave scars, while its more serious manifestations damage internal organs, and can cause death in patients with weakened immune systems. Four partners have been recruited for the project: the Dead Sea and Arava Science Center, which has identified 70 plant extracts that may be relevant for fighting the parasite; the Swiss Tropical and Public Health Institute, which will test the efficacy of the extracts on leishmaniasis samples; Pharmaseed, which is coordinating the project and is responsible for safety tests, and for assessing the potential efficacy of the extracts being tested; and Jordan University of Science and Technology Prof. Nabil Hailat, who will carry out advanced live and clinical trials (on humans) in Jordan, should these tests yield results.

Pharmaseed project founder Dr. Emmanuel Loeb explains, “50% of our work is for European companies that come to carry out tests here, in the Holy Land. This activity is growing, but the political reality is working against us, and it harms us and many other businesses. We wanted to carry out a joint project in order to solve the troubling problem, to improve regional dialogue, and also to show people overseas that good things happen here too, ” he says.

Published by Globes [online], Israel business news – www.globes-online.com

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.